Institutional

Hospital Clínic, the UB and ARTIDIS collaborate to investigate a novel diagnostic and treatment optimization approach in patients with lung cancer

Hospital Clínic and the University of Barcelona collaborate with ARTIDIS AG, a privately held health-tech company, to investigate the ARTIDIS AFM technology as a novel diagnostic tool for patients with non-small cell lung carcinoma (NSCLC), the most frequent type of lung cancer. The research partners will identify biomarkers that will enable fast and accurate lung cancer diagnosis in a clinical bedside setting. Based on the combination of results from these novel nanomechanical signatures with additional patient information in the ARTIDISNet platform, a targeted and individualized treatment approach for each patient can be identified.